 | • レポートコード：MRC2206A023 • 出版社/出版日：Persistence Market Research / 2022年4月13日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：バイオ |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートでは、世界の腫瘍研究用マウスモデル市場について広く調査・分析し、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症による危機分析、需要分析・予測、製品別（ヒト化免疫系マウスモデル、同系腫瘍マウスモデル、免疫不全マウスモデル、NOGマウスモデル、自然発生腫瘍マウスモデル）分析、エンドユーザー別（CRO、医薬品・バイオ医薬品会社、学術・研究機関）分析、地域別分析、市場構造分析、競争分析、仮定、調査手法などの項目を掲載しております。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症による危機分析 ・需要分析・予測 ・世界の腫瘍研究用マウスモデル市場規模：製品別（ヒト化免疫系マウスモデル、同系腫瘍マウスモデル、免疫不全マウスモデル、NOGマウスモデル、自然発生腫瘍マウスモデル） ・世界の腫瘍研究用マウスモデル市場規模：エンドユーザー別（CRO、医薬品・バイオ医薬品会社、学術・研究機関） ・世界の腫瘍研究用マウスモデル市場規模：地域別 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Oncology Mice Models Market – Scope of Report
The latest publication by Persistence Market Research on the oncology mice models market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for oncology mice models and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the oncology mice models market. The insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the oncology mice models market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the oncology mice models market are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the oncology mice models market offers information divided into three important segments — product, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product
Humanized Immune System Mice Models
Syngeneic Tumor Mice Models
Immunodeficient Mice Models
NOG Mice Models
Spontaneous Tumor Mice Models
Others
End User
Contract Research Organizations
Pharma and Biopharma Companies
Academic and Research Institutes
Region
North America
Latin America
Europe
Asia Pacific
Middle East and Africa (MEA)
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for oncology mice models over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the oncology mice models market avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the oncology mice models market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the oncology mice models market more accurate and reliable
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Oncology Drugs – Pipeline Analysis
4.1.1. By Intervention
4.1.2. By Phase
4.1.3. By Funding Authority
4.2. Immuno-Oncology Drugs – Pipeline Analysis
4.2.1. By Phase
4.2.2. By Funding Authority
4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials
4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials
4.5. List of Preclinical CROs
4.6. Parent Market Analysis
4.7. Relative Number of Combination Oncology Therapy Trials
4.8. Landscape of Immuno-Oncology Drug Development
4.9. List of Preclinical immuno-oncology models
4.9.1. Cell lines
4.9.2. Mice Models
4.9.3. Organoids/ spheroids
4.10. Key Regulatory Scenario
4.11. Porter’s Analysis
4.12. PESTLE Analysis
4.13. Supply Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.2. Forecast Factors – Relevance & Impact
5.2.1. Covid-19 Pandemic
5.2.2. Prevalence of cancer
5.2.3. Rise in R&D investments
5.2.4. Stringent Regulations
5.2.5. Rise in number of pre-clinical and clinical studies
5.2.6. Increasing investment in Cancer research
5.2.7. GDP Growth
5.2.8. Advancements in Models
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
6.5. Recovery Scenario – Short term, Midterm, and Long Term Impact
7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017– 2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022–2032
8.3.1. Humanized Immune System Mice Models
8.3.2. Syngeneic Tumor Mice Models
8.3.3. Immunodeficient Mice Models
8.3.4. NOG Mice Models
8.3.5. Spontaneous Tumor Mice Models
8.3.6. Others
8.4. Market Attractiveness Analysis By Product
9. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032
9.3.1. Contract Research Organizations
9.3.2. Pharma and Biopharma Companies
9.3.3. Academic and Research Institutes
9.4. Market Attractiveness Analysis By Indication
10. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021
10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
10.3.1. The North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa (MEA)
10.4 Market Attractiveness Analysis
11. North America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021
11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
11.3.1. By Country
11.3.2. By Product
11.3.3. By End User
11.4. Market Attractiveness Analysis
11.5. Key Market Participants – Intensity Mapping
11.6. Drivers and Restraints – Impact Analysis
12. Latin America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.2. By Product
12.3.3. By End User
12.4. Market Attractiveness Analysis
12.5. Key Market Participants – Intensity Mapping
12.6. Drivers and Restraints – Impact Analysis
13. Europe Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.2. By Product
13.3.3. By End User
13.4. Market Attractiveness Analysis
13.5. Key Market Participants – Intensity Mapping
13.6. Drivers and Restraints – Impact Analysis
14. Asia Pacific Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.2. By Product
14.3.3. By End User
14.4. Market Attractiveness Analysis
14.5. Key Market Participants – Intensity Mapping
14.6. Drivers and Restraints – Impact Analysis
15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.2. By Product
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.5. Key Market Participants – Intensity Mapping
15.6. Drivers and Restraints – Impact Analysis
16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032
16.1. Introduction
16.1.1. Market Value Proportion Analysis
16.1.2. Global VS. Country Growth Comparison
16.2. U.S. Medical Cart Market Analysis
16.2.1. By Product
16.2.2. By End User
16.3. Canada Medical Cart Market Analysis
16.3.1. By Product
16.3.2. By End User
16.4. Brazil Medical Cart Market Analysis
16.4.1. By Product
16.4.2. By End User
16.5. Argentina Medical Cart Market Analysis
16.5.1. By Product
16.5.2. By End User
16.6. Mexico Medical Cart Market Analysis
16.6.1. By Product
16.6.2. By End User
16.7. Germany Medical Cart Market Analysis
16.7.1. By Product
16.7.2. By End User
16.8. Italy Medical Cart Market Analysis
16.8.1. By Product
16.8.2. By End User
16.9. France Medical Cart Market Analysis
16.9.1. By Product
16.9.2. By End User
16.10. U.K. Medical Cart Market Analysis
16.10.1. By Product
16.10.2. By End User
16.11. Spain Medical Cart Market Analysis
16.11.1. By Product
16.11.2. By End User
16.12. BENELUX Medical Cart Market Analysis
16.12.1. By Product
16.12.2. By End User
16.13. Russia Medical Cart Market Analysis
16.13.1. By Product
16.13.2. By End User
16.14. China Medical Cart Market Analysis
16.14.1. By Product
16.14.2. By End User
16.15. Japan Medical Cart Market Analysis
16.15.1. By Product
16.15.2. By End User
16.16. India Medical Cart Market Analysis
16.16.1. By Product
16.16.2. By End User
16.17. Australia and New Zealand Medical Cart Market Analysis
16.17.1. By Product
16.17.2. By End User
16.18. GCC Countries Medical Cart Market Analysis
16.18.1. By Product
16.18.2. By End User
16.19. South Africa Medical Cart Market Analysis
16.19.1. By Product
16.19.2. By End User
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Share Analysis of Top Players
18. Competition Analysis
18.1. Competition Benchmarking
18.2. Competition Dashboard
18.3. Competition Deep Dive
18.3.1. The Jackson Laboratory
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Key Financials
18.3.1.4. SWOT Analysis
18.3.1.5. Sales Footprint
18.3.1.6. Strategy Overview
18.3.1.6.1. Marketing Strategy
18.3.1.6.2. Product Strategy
18.3.1.6.3. Channel Strategy
18.3.2. Taconic Biosciences
18.3.2.1. Overview
18.3.2.2. Product Portfolio
18.3.2.3. Key Financials
18.3.2.4. SWOT Analysis
18.3.2.5. Sales Footprint
18.3.2.6. Strategy Overview
18.3.2.6.1. Marketing Strategy
18.3.2.6.2. Product Strategy
18.3.2.6.3. Channel Strategy
18.3.3. Charles River Laboratories
18.3.3.1. Overview
18.3.3.2. Product Portfolio
18.3.3.3. Key Financials
18.3.3.4. SWOT Analysis
18.3.3.5. Sales Footprint
18.3.3.6. Strategy Overview
18.3.3.6.1. Marketing Strategy
18.3.3.6.2. Product Strategy
18.3.3.6.3. Channel Strategy
18.3.4. Shanghai Model Organisms Center Inc.
18.3.4.1. Overview
18.3.4.2. Product Portfolio
18.3.4.3. Key Financials
18.3.4.4. SWOT Analysis
18.3.4.5. Sales Footprint
18.3.4.6. Strategy Overview
18.3.4.6.1. Marketing Strategy
18.3.4.6.2. Product Strategy
18.3.4.6.3. Channel Strategy
18.3.5. Envigo
18.3.5.1. Overview
18.3.5.2. Product Portfolio
18.3.5.3. Key Financials
18.3.5.4. SWOT Analysis
18.3.5.5. Sales Footprint
18.3.5.6. Strategy Overview
18.3.5.6.1. Marketing Strategy
18.3.5.6.2. Product Strategy
18.3.5.6.3. Channel Strategy
18.3.6. Biocytogen
18.3.6.1. Overview
18.3.6.2. Product Portfolio
18.3.6.3. Key Financials
18.3.6.4. SWOT Analysis
18.3.6.5. Sales Footprint
18.3.6.6. Strategy Overview
18.3.6.6.1. Marketing Strategy
18.3.6.6.2. Product Strategy
18.3.6.6.3. Channel Strategy
18.3.7. Genoway
18.3.7.1. Overview
18.3.7.2. Product Portfolio
18.3.7.3. Key Financials
18.3.7.4. SWOT Analysis
18.3.7.5. Sales Footprint
18.3.7.6. Strategy Overview
18.3.7.6.1. Marketing Strategy
18.3.7.6.2. Product Strategy
18.3.7.6.3. Channel Strategy
18.3.8. Crown Bioscience Inc. (JSR Corporation).
18.3.8.1. Overview
18.3.8.2. Product Portfolio
18.3.8.3. Key Financials
18.3.8.4. SWOT Analysis
18.3.8.5. Sales Footprint
18.3.8.6. Strategy Overview
18.3.8.6.1. Marketing Strategy
18.3.8.6.2. Product Strategy
18.3.8.6.3. Channel Strategy
18.3.9. Cyagen
18.3.9.1. Overview
18.3.9.2. Product Portfolio
18.3.9.3. Key Financials
18.3.9.4. SWOT Analysis
18.3.9.5. Sales Footprint
18.3.9.6. Strategy Overview
18.3.9.6.1. Marketing Strategy
18.3.9.6.2. Product Strategy
18.3.9.6.3. Channel Strategy
18.3.10. Applied stem cells
18.3.10.1. Overview
18.3.10.2. Product Portfolio
18.3.10.3. Key Financials
18.3.10.4. SWOT Analysis
18.3.10.5. Sales Footprint
18.3.10.6. Strategy Overview
18.3.10.6.1. Marketing Strategy
18.3.10.6.2. Product Strategy
18.3.10.6.3. Channel Strategy
18.3.11. Ingenious Targeting Laboratory
18.3.11.1. Overview
18.3.11.2. Product Portfolio
18.3.11.3. Key Financials
18.3.11.4. SWOT Analysis
18.3.11.5. Sales Footprint
18.3.11.6. Strategy Overview
18.3.11.6.1. Marketing Strategy
18.3.11.6.2. Product Strategy
18.3.11.6.3. Channel Strategy
18.3.12. PolyGene – Transgenic mice model company
18.3.12.1. Overview
18.3.12.2. Product Portfolio
18.3.12.3. Key Financials
18.3.12.4. SWOT Analysis
18.3.12.5. Sales Footprint
18.3.12.6. Strategy Overview
18.3.12.6.1. Marketing Strategy
18.3.12.6.2. Product Strategy
18.3.12.6.3. Channel Strategy
18.3.13. Creative Biolabs
18.3.13.1. Overview
18.3.13.2. Product Portfolio
18.3.13.3. Key Financials
18.3.13.4. SWOT Analysis
18.3.13.5. Sales Footprint
18.3.13.6. Strategy Overview
18.3.13.6.1. Marketing Strategy
18.3.13.6.2. Product Strategy
18.3.13.6.3. Channel Strategy
18.3.14. TransCure Bioservices
18.3.14.1. Overview
18.3.14.2. Product Portfolio
18.3.14.3. Key Financials
18.3.14.4. SWOT Analysis
18.3.14.5. Sales Footprint
18.3.14.6. Strategy Overview
18.3.14.6.1. Marketing Strategy
18.3.14.6.2. Product Strategy
18.3.14.6.3. Channel Strategy
18.3.15. Champions Oncology Inc
18.3.15.1. Overview
18.3.15.2. Product Portfolio
18.3.15.3. Key Financials
18.3.15.4. SWOT Analysis
18.3.15.5. Sales Footprint
18.3.15.6. Strategy Overview
18.3.15.6.1. Marketing Strategy
18.3.15.6.2. Product Strategy
18.3.15.6.3. Channel Strategy
18.3.16. Certis Oncology
18.3.16.1. Overview
18.3.16.2. Product Portfolio
18.3.16.3. Key Financials
18.3.16.4. SWOT Analysis
18.3.16.5. Sales Footprint
18.3.16.6. Strategy Overview
18.3.16.6.1. Marketing Strategy
18.3.16.6.2. Product Strategy
18.3.16.6.3. Channel Strategy
18.3.17. Signature
18.3.17.1. Overview
18.3.17.2. Product Portfolio
18.3.17.3. Key Financials
18.3.17.4. SWOT Analysis
18.3.17.5. Sales Footprint
18.3.17.6. Strategy Overview
18.3.17.6.1. Marketing Strategy
18.3.17.6.2. Product Strategy
18.3.17.6.3. Channel Strategy
18.3.18. Pharmaron
18.3.18.1. Overview
18.3.18.2. Product Portfolio
18.3.18.3. Key Financials
18.3.18.4. SWOT Analysis
18.3.18.5. Sales Footprint
18.3.18.6. Strategy Overview
18.3.18.6.1. Marketing Strategy
18.3.18.6.2. Product Strategy
18.3.18.6.3. Channel Strategy
18.3.19. Laboratory Corporation of America Holdings
18.3.19.1. Overview
18.3.19.2. Product Portfolio
18.3.19.3. Key Financials
18.3.19.4. SWOT Analysis
18.3.19.5. Sales Footprint
18.3.19.6. Strategy Overview
18.3.19.6.1. Marketing Strategy
18.3.19.6.2. Product Strategy
18.3.19.6.3. Channel Strategy
18.3.20. Gempharmatech
18.3.20.1. Overview
18.3.20.2. Product Portfolio
18.3.20.3. Key Financials
18.3.20.4. SWOT Analysis
18.3.20.5. Sales Footprint
18.3.20.6. Strategy Overview
18.3.20.6.1. Marketing Strategy
18.3.20.6.2. Product Strategy
18.3.20.6.3. Channel Strategy
18.3.21. Janvier Labs
18.3.21.1. Overview
18.3.21.2. Product Portfolio
18.3.21.3. Key Financials
18.3.21.4. SWOT Analysis
18.3.21.5. Sales Footprint
18.3.21.6. Strategy Overview
18.3.21.6.1. Marketing Strategy
18.3.21.6.2. Product Strategy
18.3.21.6.3. Channel Strategy
18.3.22. Harbour BioMed
18.3.22.1. Overview
18.3.22.2. Product Portfolio
18.3.22.3. Key Financials
18.3.22.4. SWOT Analysis
18.3.22.5. Sales Footprint
18.3.22.6. Strategy Overview
18.3.22.6.1. Marketing Strategy
18.3.22.6.2. Product Strategy
18.3.22.6.3. Channel Strategy
19. Assumptions and Acronyms Used
20. Research Methodology
Table 01: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by ProductTable 02: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by End User
Table 03: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Region
Table 04: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product
Table 05: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 06: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product
Table 07: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 08: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product
Table 09: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 10: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product
Table 11: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User
Table 12: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product
Table 13: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User